Background {#Sec1}
==========

Pulmonary surfactant is a complex mixture of lipids, primarily dipalmitoylphosphatidylcholine, surfactant proteins (SP-A, SP-B, SP-C, and SP-D), and the protein adenosine triphosphate-binding cassette subfamily A member 3 (ABCA3), produced by type II pneumocytes. Pulmonary surfactant is essential for lowering surface tension at the air--liquid interface to prevent end-expiratory alveolar collapse. Lamellar bodies are dense multilayer secretory organelles found in pneumocytes II which store the surfactant \[[@CR1]\]. Mutations in SP-C, SP-D, and ABCA3 have been related to surfactant dysfunction and neonatal respiratory failure (NRF) in full-term babies and interstitial lung disease (ILD) in older children and adults \[[@CR2]\].

ABCA3 is a protein expressed predominantly in the lung, localized to the limiting membrane of lamellar bodies of type II pneumocytes. The ABCA3 protein is codified by a single gene located in chromosome 16 which consists of 33 exons \[[@CR3]\]. It has been demonstrated that ABCA3 selectively facilitates the transfer of phosphatidylcholine, sphingomyelin, and cholesterol to lamellar bodies \[[@CR4]\].

Autosomic recessive mutations in the *ABCA3* gene have been frequently involved in NRF due to surfactant deficiency and some forms of ILD in older children. The majority of these identified mutations are located in the exons or the immediate intron--exon boundaries. A recent article identified an intronic *ABCA3* mutation in one allele and a known disease causing mutation in the other as responsible for NRF in a full-term newborn \[[@CR5]\]. We report the case of a full-term baby boy with a homozygous intronic *ABCA3* mutation as the cause of his fatal respiratory disease.

Case presentation {#Sec2}
=================

We describe the case of a full-term Colombian newborn baby boy who was the product of a primigravid mother, and non-consanguineous parents of mixed race ancestry (Mestizo). Fetal monitoring at the 37th week gestational age showed continuous decelerations. A caesarean section was performed and he was delivered with severe respiratory depression. Management with noninvasive positive-pressure ventilation was started without success. He was transferred to our intensive care unit and intubation was performed. An echocardiogram showed moderate pulmonary hypertension. Chest X-rays showed complete bilateral opacity of both lungs. Initial treatment with artificial surfactant was offered without success (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Anteroposterior chest radiograph from a newborn baby boy showing bilateral diffuse hazy granular pulmonary opacification

Blood tests showed 38,900 leukocytes with 90 % neutrophils, but the results of all the cultures and the C-reactive protein were negative. A lung biopsy was performed. Right apical pneumothorax appeared as a complication of the procedure and was treated with a chest tube. The lung biopsy showed minimal interstitial changes, preserved alveolar architecture, hyperplasia of the alveolar epithelium (pneumocytes type 2) and a thickened septum full of mesenchymal immature cells and few inflammatory cells (some eosinophils, neutrophils, and leukocytes; Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Panels **a** and **b** are different plates from the lung biopsy showing pulmonary alveolar proteinosis pattern characterized by type II pneumocytes hyperplasia, interstitial widening, and fine granular proteinosis material admixed with foamy macrophages

During his hospitalization, his fever persisted; his leukocytosis was treated with vancomycin and meropenem without any bacteriological finding. He died on day 60 due to respiratory failure and the diagnosis was still uncertain.

Based on the suspicion of a SP deficiency, the genes for SP-B and exon 9 for *ABCA3* gene were analyzed without finding any abnormalities. Exon 4 of the *SP-C* gene showed the polymorphism Thr138Asn in the heterozygous form (ACT/AAT) and exon 5 the Asn186Asn polymorphism in the homozygous form (AAC/AAC).

Due to the uncertainty of the diagnosis a literature review was performed and experts were asked for advice. A search for a specific mutation in the intronic region of the *ABCA3* gene was performed. In intron 25 at position --98 from exon 26 a homozygous C\>T transition mutation was detected. This mutation changes the intronic sequence, creates a new donor splice site and leads to aberrant ABCA3 proteins and is the cause of our patient's fatal respiratory disease (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3*ABCA3*, exon 26 sequence from 45981 to 46336 showing homozygous mutation IVS25 (gttacagg**T**gccttgag)

To confirm the mechanism of inheritance of the disease and to be able to perform proper genetic counseling, genetic sequencing for the specific gene was done on both parents and both are carriers of the mutation IVS25-98 T.

Discussion {#Sec3}
==========

The most common presentation of a baby with *ABCA3* mutation that leads to NRF is a full-term baby with moderate to severe respiratory distress and signs of diffuse lung disease without satisfactory history or laboratory findings. The disease is often progressive and fatal within the first 3 months of life even with proper therapy as occurred in this case \[[@CR6]--[@CR14]\]. Some cases of older children with ILD and *ABCA3* mutations have been reported. Out of the four reported cases of patients with a IVS25-98 T mutation in one allele, two died, one of them received a lung transplant and the other one is still alive but has ILD (see Table [1](#Tab1){ref-type="table"}) \[[@CR5], [@CR7]--[@CR14]\].Table 1Characteristics of patients with *ABCA3* mutationAuthorPatientEthnicityPresentationAllele 1 mutationAllele 2 mutationFindings consistent with ABCA3 deficiencyOutcomeGenotypeYoung *et al*. 2008 \[[@CR7]\]15 y/o, indolent exercise intolerance, and chest discomfortc1--28\>G?Alive; no clinical, physiologic, or radiographic progressionHeterozygous for *ABCA3*IVS9 + 11C\>T?c3765C\>G?Hofmeister *et al*. 2008 \[[@CR8]\]ProbandAfricanNewborn, respiratory distress syndrome578C\>G578C\>GDiedHomozygous for *ABCA3*Proband's brotherAfricanNewborn, respiratory distress syndrome578C\>G578C\>GDiedHomozygous for *ABCA3*Agrawal *et al*. 2012 \[[@CR5]\]AWhiteNewborn, respiratory distress syndromep.E690KIVS25-98TLung histopathology and electron microscopyDiedBWhiteRespiratory distress syndromep.L941PIVS25-98TFamily history of sibling with fatal respiratory distress syndromeDiedHeterozygous for *ABCA3*CWhite8 y/o, interstitial lung diseaseL212M?Mutation associated with disease in other patientsAlive with interstitial lung diseaseDWhiteNewborn, respiratory distress syndromec.4903ins5?Family history of two siblings with fatal respiratory distress syndrome, lung histopathology, and electron microscopyDiedE, FWhiteNewborn, respiratory distress syndromep.E1325K?DiedGHispanic2 months, interstitial lung diseasep.R43CIVS25-98TLung histopathology and electron microscopyLung transplantHeterozygous for *ABCA3* IVS25-98C\>THHispanicNewborn, respiratory distress syndromep.A1070T?Mutation associated with disease in other patients, lung histopathologyAlive with interstitial lung diseaseIWhiteNewborn, respiratory distress syndromep.R43HIVS25-98TMutation associated with disease in other patients, lung histopathologyAlive with interstitial lung diseaseHeterozygous for *ABCA3*JAfrican-AmericanInterstitial lung diseasep.R280C?Mutation associated with disease in other patients, lung histopathologyAlive with interstitial lung diseaseKWhiteinterstitial lung diseasep.N1418S?Mutation associated with disease in other patientsAlive with interstitial lung diseaseThavagnanam *et al*. 2013 \[[@CR9]\]Newborn, mild respiratory distress syndromec.447 + 11C\>Tc.2333 A\>GFamily history of sibling with fatal respiratory distress syndrome, lung histopathology, and electron microscopyAliveFour variants for *ABCA3*c.4583 C\>Tc.3755 T\>CGonçalves *et al*. 2013 \[[@CR10]\]Newborn, respiratory distress syndromeL798PR1612PLung histologyDiedCompound heterozygous mutations in *ABCA3*Panigrahy *et al*. 2014 \[[@CR11]\]Newborn, respiratory distress syndromec3703 + 1 G\>Tc3703 + 1 G\>TLung histologyDiedHomozygous for *ABCA3*Malý *et al*. 2014 \[[@CR12]\]Newborn, respiratory distress syndromec.3680 T\>Gc4289_4290insADiedTwo compound heterozygous mutations in *ABCA3*Rezaei *et al*. 2016 \[[@CR13]\]Newborn, respiratory distress syndromep.Gly202Arg/G202Rp.Gly202Arg/G202RDiedHomozygous for *ABCA3*Ota *et al*. 2016 \[[@CR14]\]Asian8 y/o, interstitial lung disease, combined pulmonary fibrosis and emphysema, and pulmonary hypertensionp.L34Pp.1203_1204delHigh resolution computed tomographyAlive with interstitial lung diseaseHeterozygous for *ABCA3*Current reportHispanicNewborn, respiratory distress syndromeIVS25-98TIVS25-98TMutation associated with disease in other patients, lung histopathologyDiedHomozygous for *ABCA3*Original table taken from Agrawal *et al*. 2012 \[[@CR5]\], and modified by the authors. *?* Unknown mutation, *y/o* year old

The histopathological findings in patients with NRF due to surfactant deficiency consist of type II pneumocytes hyperplasia, interstitial thickening, and prominent foamy macrophages in the airspaces, often embedded in variable amounts of proteinaceous material as found in the biopsy of our case. These findings are the result of an inborn error disrupting surfactant metabolism and function and are nonspecific for any of the SP-B, SP-C and ABCA3 mutations. A molecular diagnosis is needed to determine the specific mutation affecting each case \[[@CR15], [@CR16]\].

In exon 4 our patient shows the polymorphism Thr138Asn in the heterozygous form (ACT/AAT) and in exon 5 the Asn186Asn polymorphism in the homozygous form (AAC/AAC). These findings have been associated with risk of perinatal NRF in preterm male newborns. However, our patient was born at term and these polymorphisms have been frequently found in healthy people. Therefore, one may conclude that the analysis of the five coding *SP-C* exons does not support surfactant deficiency or a fatal malfunction of surfactant transport \[[@CR17]\].

Definitive diagnosis required examination of DNA for *ABCA3* intronic mutations. The analysis of the mutation IVS25-98 T was performed and a homozygous mutation was detected. This intronic mutation has been previously reported in heterozygous patients with severe NRF. The genetic analysis of such patients showed one allele with the intronic mutation and an exonic mutation in the other one. It is known that the IVS-98 T is a NRF-causing *ABCA3* mutation since the intronic sequence creates a new donor splice site which leads to aberrantly spliced transcripts. It is suggested that the additional amino acids added to the ABCA3 protein alter its intracellular routing, stability, and function \[[@CR5]\]. Recently, intronic mutations have been found in cystic fibrosis as disease-causing mutations in patients without a previously identified exonic mutation \[[@CR18]\].

The literature reports four additional cases homozygous for *ABCA3* IVS25-98 T. The four babies were unrelated, no history of consanguinity was identified, but all of them came from South America \[[@CR5]\]. Although the mechanism of inheritance is still unclear and isodisomic uniparental disomy has been reported for ABCA3 deficiency, we speculate through our findings that the mechanism of inheritance could be autosomic recessive and the ethnical similarities of the cases could suggest a possible founder effect for this population \[[@CR6]\]. Further larger population-based studies are required to determine the real frequency of IVS25-98 T in this population.

In spite of the fact that establishing the diagnosis did not alter the outcome of the patient and usually the diagnosis is established after the decease of the patient, it is essential to adequately counsel the parents and family members of the recurrence risk. Our patient's parents were encouraged to have their *ABCA3* gene screened for the IVS25-98 T mutation. Both parents of our patient are heterozygous carriers of the IVS25-98 T mutation in the *ABCA3* gene. Therefore, children have a chance of 25 % of being affected by lethal ABCA3 deficiency and 50 % of being carriers. Two sisters of our patient's father are heterozygous carriers of the IVS25-98 T mutation in the *ABCA3* gene. Their partners do not carry the IVS25-98 T mutation, thus children of both couples have a statistical chance of 25 % of being heterozygous carriers of the mutation and none of them will be affected.

Conclusions {#Sec4}
===========

The clinical presentation of this case is consistent with a case of NRF due to surfactant deficiency. The histopathological findings in patients with NRF due to surfactant deficiency are nonspecific for any of the SP-B, SP-C and ABCA3 mutations and a molecular diagnosis is needed. The analysis of the five coding *SP-C* exons does not support surfactant deficiency or a fatal malfunction of surfactant transport due to *SP-C* mutations as the cause for our patient's symptoms. Without evidence of a previously identified *ABCA3* mutation in an exon or an immediate intron--exon boundary, we conclude that the homozygous IVS25-98 T mutation is responsible for this case's NRF. The findings of our patient's relatives suggest an autosomic recessive pattern of inheritance. Genetic counseling was provided and the relatives are now informed of the recurrence risks and treatment options.
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